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Abstract
Background and Objectives The effects of age and sex on
apixaban pharmacokinetics and pharmacodynamics were
studied.
Methods This was an open-label, single-dose, 2 9 2
factorial study. Healthy young (aged 18–40 years) and
elderly (aged C65 years) male and female subjects
received a single oral 20 mg dose of apixaban. Blood and
urine samples were collected for pharmacokinetic and
pharmacodynamic (blood only) analyses. Subjects were
monitored for adverse events throughout the study.
Results Seventy-nine subjects were enrolled into four
groups: young males (n = 20), elderly males (n = 20),
young females (n = 20) and elderly females (n = 19). Age
did not affect the maximum observed plasma concentration
(Cmax). The mean area under the concentration–time curve
from time zero extrapolated to infinite time (AUC?) was
32 % greater in elderly subjects than in young subjects.
The mean Cmax and AUC? values were 18 and 15 %
higher, respectively, in females than in males. The time
course of the mean international normalized ratio (INR),
modified prothrombin time (mPT) and anti-Xa activity
tracked the apixaban concentration–time curve. All three
pharmacodynamic measures exhibited a positive linear
correlation with the plasma apixaban concentration. Dif-
ferences in the mean INR, mPT and anti-Xa activity
between age and sex groups were small (\15 % at the
maximum mean values) and were generally related to
pharmacokinetic differences. However, anti-Xa activity
demonstrated less variability than the INR or mPT, and
may have utility as a bioassay for apixaban. Apixaban was
well tolerated, with no serious adverse events.
Conclusion There were no clinically meaningful age- or
sex-related differences in the pharmacokinetics and phar-
macodynamics of apixaban that would require dose mod-
ification on the basis of age or sex alone.
Key Points
In this study, there were no clinically meaningful
age- or sex-related differences in the
pharmacokinetics and pharmacodynamics of
apixaban.
Apixaban is safe and well tolerated in both elderly
and young subjects of both sexes.
Dose adjustment of apixaban is not required on the
basis of age or sex alone.
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1 Background
Anticoagulation plays an important role in the prevention
and treatment of venous and arterial thrombosis [1–3].
Conventional anticoagulants, such as unfractionated hepa-
rin, low molecular weight heparin (LMWH) and warfarin,
have limitations that may contribute to suboptimal patient
management [3–5]. In recent years, considerable effort has
been directed towards the development of orally adminis-
tered anticoagulants that have a rapid onset of action,
predictable pharmacokinetics and pharmacodynamics, and
a low propensity for food and drug interactions. Targets of
these new oral anticoagulants include clotting factors such
as factor Xa (FXa) and thrombin.
Apixaban is a novel oral, selective, direct-acting, revers-
ible FXa inhibitor, which was approved in several countries
for prevention of venous thromboembolism (VTE) in
patients following elective knee or hip replacement surgery
and for reduction in the risk of stroke or systemic embolism
in patients with nonvalvular atrial fibrillation (NVAF), and
recently for the treatment of venous thromboembolism.
Apixaban has oral bioavailability of *50 % and multiple
pathways of elimination (including renal elimination,
metabolism, biliary excretion and direct intestinal excretion),
with renal clearance (CLR) accounting for 27 % of total
clearance [6–8]. The average elimination half-life (t) is
approximately 12 h (range 8–15 h) [9].
Numerous studies have shown that age and sex have the
potential to influence the pharmacokinetics and pharmaco-
dynamics of some drugs, including anticoagulants [10–14].
Physiological changes associated with aging, such as
increased gastric pH, reduced lean body mass, decreased
liver size and hepatic blood flow, and a decreased glomer-
ular filtration rate, can affect the absorption, distribution,
metabolism and excretion of drugs [10]. The incidence and
prevalence of many thromboembolic disorders, such as
NVAF, increase with advancing age, as does the need for
major orthopaedic surgery [1, 15]. Sex-related differences in
drug pharmacokinetics have also been attributed to physio-
logical differences between males and females [11, 14]. The
primary objective of this study was to assess the effects of
age and sex on the single-dose pharmacokinetics of apix-
aban. Secondary objectives were to assess the effects of age
and sex on the single-dose pharmacodynamics of apixaban,
along with the safety and tolerability profile.
2 Methods
2.1 Study Design
This was an open-label, single-dose, 2 9 2 factorial study
in both young and elderly healthy subjects, who received a
single oral 20 mg dose of apixaban (clinical supply; Bris-
tol-Myers Squibb, New Brunswick, NJ, USA). This was the
highest dose evaluated in phase 2 studies [16, 17] and was
expected to be well tolerated on the basis of previous
experience [7]. This study was conducted at a single centre
(Seaview Research, Miami, FL, USA), and the protocol
and informed consent were reviewed and approved by an
independent investigational review board (Plantation, FL,
USA). The study was conducted in accordance with the
codes and guidelines of the Declaration of Helsinki, Good
Clinical Practice and all applicable laws and regulations.
Subjects were grouped by age (young and elderly) and
sex. Given a null hypothesis of no age- or sex-specific
differences in pharmacokinetics, data from 76 subjects (19
subjects per age/sex group) would provide 97 % power to
conclude absence of effects with respect to the area under
the plasma concentration–time curve (AUC) from time
zero extrapolated to infinite time (AUC?) and the maxi-
mum observed plasma concentration (Cmax) [i.e. with the
90 % confidence intervals (CIs) of the geometric mean
ratios being within 80–125 %]. These calculations assumed
that there is no age-by-sex interaction and that the AUC?
and Cmax are log-normally distributed with coefficients of
variation of 25 %, as estimated from a previous study [7].
To allow for possible dropouts, it was planned that 80
subjects would be treated (20 subjects per age/sex group).
Subjects who signed the informed consent form were
enrolled into the following four groups: young men (aged
18–40 years), elderly men (aged C65 years), young
women (aged 18–40 years) and elderly women
(aged C65 years). Subjects were admitted to the clinical
facility 2 days prior to dosing (day -2) and remained until
96 h postdose (day 5). On day 1, after fasting overnight for
at least 10 h, subjects received a single oral dose of 20 mg
apixaban. Blood and urine samples were collected for
pharmacokinetic and pharmacodynamic (blood only)
analyses at intervals up to 96 h postdose. Physical exam-
inations (including vital sign measurements), 12-lead
electrocardiograms and clinical laboratory evaluations
were performed at baseline and prior to study discharge.
2.2 Study Population
Healthy male and female subjects aged 18–40 years
or C65 years and with a body mass index (BMI) of
18–32 kg/m2 were eligible for the study. The exclusion
criteria included evidence or history of a bleeding disorder;
history of gastrointestinal disease or surgery that could
interfere with the absorption of apixaban; and use of any
hormonal contraceptive within 3 months before dosing,
any prescription drug or over-the-counter acid controller
within 4 weeks before dosing, drugs known to increase the
potential for bleeding [such as aspirin, nonsteroidal anti-
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inflammatory drugs (NSAIDs) or anticoagulants] within
2 weeks before dosing or any other drugs (including over-
the-counter medications or dietary supplements) within
1 week before dosing.
2.3 Sample Collection and Assay
Venous blood samples (4.5 mL) were collected in sodium
citrate (3.2 %) tubes at 0 h (predose) and at 1, 1.5, 2, 3, 4,
6, 8, 10, 12, 18, 24, 36, 48, 72 and 96 h postdose for the
pharmacokinetic and pharmacodynamic analyses. Phar-
macokinetic blood samples were centrifuged for 15 min at
1,5009g at 4 C, and the plasma was transferred to 4 mL
cryogenic vials, which were frozen immediately in dry ice
and stored for shipment at -20 C. Following a predose
void, subjects provided urine samples for the time intervals
of 0–12, 12–24, 24–36, 36–48, 48–60, 60–72 and 72–96 h
after dosing. For each collection interval, the urine volume
was recorded and aliquots of the urine samples were col-
lected and stored (frozen at -20 C) until shipment to the
analytical laboratory. Apixaban was quantitatively deter-
mined in plasma and urine samples by Intertek Pharma-
ceutical Services (El Dorado Hills, CA, USA), using
validated high-performance liquid chromatographic–tan-
dem mass spectrometric methods. The assay was per-
formed on an AB Sciex 3000TM system using Analyst 1.4
software. Plasma and urine samples were extracted using
protein precipitation and solid-phase extraction, respec-
tively. The lower limit of quantification was 1.0 ng/mL for
both apixaban plasma and urine assays. The standard
curves were fitted by a 1/x2-weighted linear equation over
the concentration range of 1.00–1,000 ng/mL. The
between-run and within-run variability, expressed as
coefficients of variation, for apixaban in quality-control
plasma samples were B9.49 and B10.1 %, respectively,
with deviations from the nominal concentration of no more
than ± 16.2 %. The between-run and within-run variabil-
ity for apixaban in quality-control urine samples
were B3.65 and B3.58 %, respectively, with deviations
from the nominal concentration of no more than ± 12.4 %.
All of the runs for the study met the acceptance criteria.
The international normalized ratio (INR), modified
prothrombin time (mPT) and anti-Xa activity were mea-
sured to assess apixaban pharmacodynamic activity. Two
4.5 mL venous blood samples per time point were col-
lected in 3.2 % sodium citrate tubes and centrifuged for
10 min at 2,5009g at 4 C. The two plasma supernatants
were pooled and then centrifuged again for 10 min at
2,5009g at 4 C to minimize the platelet content in the
plasma. Aliquots of the plasma sample were transferred
into separate cryovials for INR, mPT and anti-Xa activity
analysis and were stored at or below -20 C for shipment
to the analytical laboratories.
The INR was measured by MDS (Toronto, ON, Can-
ada), using an MLA 1600/1800 coagulation analyser and
Hemoliance RecombiPlasTin reagent (Beckman Coulter,
Inc., Brea, CA, USA), having an international sensitivity
index of *1.0 (normal range 0.9–1.3), with results repor-
ted to one decimal point. The mPT was measured by a
validated method at Covance Laboratories, Inc. (Chantilly,
VA, USA), using an MLA 1600c coagulation analyser
(assay range 7–600 s). For the mPT assay, the thrombo-
plastin reagent (Dade Thromboplastin C Plus; Siemens
Healthcare Diagnostics, Deerfield, IL, USA) was diluted
1:2.25 with 100 nmol/L calcium chloride to decrease the
rate of the clotting reaction [18]. Analyses of anti-Xa
activity were performed by the Clinical Discovery Tech-
nologies group at Bristol-Myers Squibb (Hopewell, NJ,
USA). Anti-Xa activity was measured using an STA-
Rotachrom heparin kit (Diagnostica Stago, Parsippany,
NJ, USA) on an STA-R analyser [19]. Apixaban anti-Xa
activity was calculated as the inverse of colour generation
measured at 405 nm and interpolated against a 3-point
linear kit LMWH calibration curve [range 0–2 IU/mL
(LMWH units)] and against a 9-point log-linear apixaban
calibration curve [range 7.8–2,000 ng/mL (apixaban
units)].
2.4 Pharmacokinetic and Pharmacodynamic
Assessments
Single-dose pharmacokinetic parameters were calculated
from the individual plasma apixaban concentration–time
data, using noncompartmental methods, by Kinetica
(version 4.2; InnaPhase Corp., Philadelphia, PA, USA)
within the eToolbox Software package (EP version 2.4;
Thermo Electron Corporation, Philadelphia, PA, USA).
The parameters included Cmax, the time of Cmax (tmax),
AUC?, AUC from time zero to the time of the last mea-
surable concentration (AUClast) and t. If the extrapolated
AUC was greater than 20 % of the subject’s AUC?, the
subject was excluded from summaries of AUC? and t.
CLR was calculated as the total cumulative amount of drug
recovered in the urine, divided by AUClast over the same
time interval. The apparent total clearance after oral
administration (CL/F) was calculated as dose divided by
AUC?. The apparent volume of distribution at steady state
(Vss/F) was calculated as dose 9 AUMC/AUC
2, where
AUMC is the area under the first-moment curve (the area
under the first moment of the plasma concentration–time
curve).
The mean pharmacodynamics–time profiles (INR, mPT
and anti-Xa activity) for the age and sex groups were
derived from individual subject data within each group,
using the measurements collected from predose to 96 h
postdose. Maximum values were determined for the INR,
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mPT and anti-Xa activity from the mean data. The AUC
from time zero to 24 h postdose (AUC24) was calculated
for the INR and mPT from individual subject data. Given
that an exploratory anti-Xa activity method was used in this
study and not optimized for measurement of apixaban,
AUC for anti-Xa activity was not calculated.
2.5 Statistical Analysis
2.5.1 Pharmacokinetics
Summary statistics were presented by group for all apix-
aban parameters (Cmax, AUC?, AUClast, tmax, t, CL/F,
Vss/F and CLR). Geometric means and coefficients of var-
iation were provided for Cmax, AUC? and AUClast. The
median and range were presented for tmax. Arithmetic
means and standard deviations (SDs) were provided for t,
CL/F, Vss/F and CLR.
To assess the effects of age and sex on the pharma-
cokinetics of apixaban, analysis of variance was per-
formed on ln(AUC?) and ln(Cmax). The factors in the
analyses were age, sex and the interaction of age and
sex. Point estimates and 90 % CIs for means and for
differences between means on a log scale were expon-
entiated to obtain estimates of geometric means and
ratios of geometric means on the original scale. No
adjustment was made for multiplicity. Absence of an
age or sex effect on apixaban AUC? or Cmax was
concluded if the corresponding 90 % CI for the elderly
to young ratio or for the female to male ratio of the
population geometric mean was contained within an
equivalence interval of 80–125 %. Regression analyses
were conducted to assess potential relationships between
apixaban CL/F and CLR and creatinine clearance
(CLcr), apixaban exposure (AUC? and Cmax) and CLcr,
body weight and BMI.
2.5.2 Pharmacodynamics
Pharmacodynamic assessment–time profiles (means ±
SDs) were presented by age and sex groups for INR,
mPT and anti-Xa activity values (expressed in both
LMWH and apixaban units). Scatter plots of INR, mPT
and anti-Xa activity values versus the plasma apixaban
concentration were provided. The slope and intercept
(90 % CI) were provided for INR, mPT and anti-Xa
activity values (expressed in ng/mL and LMWH units)
based on the model-based regression analysis. SAS/
STAT version 8.2 software was used to perform the
statistical analyses of the pharmacokinetic and phar-
macodynamic data.
2.6 Safety Assessments
Subjects were closely monitored for adverse events
throughout the study. The incidence of adverse events was
tabulated, and all adverse events were reviewed for their
relation to apixaban and clinical importance. Blood and
urine samples for clinical laboratory testing were collected
under fasting conditions at screening, at baseline, on day 1,
on day 2 and before study discharge. In addition, 12-lead
electrocardiograms and physical examinations were per-





BMI body mass index, CLcr
creatinine clearance, SCr serum
creatinine, SD standard
deviation
a 18–40 years of age
b C65 years of age
c CLcr is based on the
Cockcroft–Gault calculation at
screening: male CLcr = [140-
age (y)] 9 weight (kg)/
[72 9 SCr (mg/dL)]; female
CLcr = 0.85 9 male CLcr
Characteristic Younga Elderlyb
Male (n = 20) Female (n = 20) Male (n = 20) Female (n = 19)
Age, years
Mean (SD) 31 (6) 34 (5) 71 (5) 69 (3)
Range 21–40 21–40 65–79 65–76
Race, n (%)
White 15 (75) 18 (90) 19 (95) 16 (84)
Black 4 (20) 2 (10) 0 3 (16)
Hispanic 1 (5) 0 1 (5) 0
Weight, kg
Mean (SD) 76.8 (12.4) 65.3 (8.9) 78.9 (12.0) 70.2 (10.8)
Range 60.0–97.0 53.7–86.0 55.0–114.0 54.0–89.0
BMI, kg/m2
Mean (SD) 26.1 (3.5) 25.4 (3.1) 28.3 (2.8) 28.4 (2.9)
Range 20.2–31.9 20.6–32.0 21.0–31.9 22.5–32.0
CLcr, mL/minc
Mean (SD) 123.3 (23.0) 115.7 (15.0) 82.8 (20.8) 75.1 (12.4)
Range 87–179 92–152 62–144 60–104
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3 Results
3.1 Study Population
A total of 79 subjects met the study criteria, were treated
and completed the study. The clinical phase of the study
was conducted from May to November 2005. The baseline
characteristics of all subjects are summarized in Table 1.
The mean age was 71 years for elderly males and 69 years
for elderly females, versus 31 and 34 years for young
males and young females, respectively.
3.2 Pharmacokinetics
The mean plasma concentration–time profiles of apixaban
for the four age and sex groups are shown in Fig. 1.
Pharmacokinetic parameters and the results of statistical
analyses of Cmax and AUC? by age and sex are shown in





















Young (n = 40)a 315.4 (34) 3,424 (32) 3,360 (32) 3.0 (1.0, 4.0) 11.98 (5.15)b 0.63 (0.33) 6.10 (1.81) 85.2 (28.2)
Elderly (n = 39)c 336.9 (27) 4,536 (23) 4,451 (23) 3.0 (1.0, 4.0) 15.45 (7.39) 0.45 (0.13) 4.52 (0.98) 77.5 (27.0)
Ratio of adjusted
GM, elderly to
young (90 % CI)
1.07 (0.96–1.19) 1.32 (1.20–1.46)
AUC? area under the plasma concentration–time curve from time zero extrapolated to infinite time, AUClast area under the plasma concentration–time
curve from time zero to the time of the last measurable concentration, CI confidence interval, CL/F apparent total clearance after oral administration,
CLR renal clearance, Cmax maximum observed plasma concentration, CV coefficient of variation, GM geometric mean, max maximum, min minimum,
SD standard deviation, t plasma terminal half-life, tmax time of Cmax, Vss/F apparent volume of distribution at steady state
a 18–40 years of age
b One young female subject was excluded from the summary statistics (and related analyses) for AUC? and t on the basis of predefined criteria
































































Fig. 1 Mean (± standard deviation) plasma concentration–time profiles of apixaban after single-dose administration (20 mg), by age and sex
groups. The error bars represent ±1 standard deviation
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Tables 2 and 3, respectively. Apixaban reached Cmax
within 3 h of administration, on average, regardless of age
or sex. Age had no effect on apixaban Cmax, whereas older
age was associated with a 32 % greater apixaban AUC?,
compared with younger age. In female subjects, the apix-
aban geometric mean Cmax and AUC? values were 18 and
15 % higher, respectively, than the values in male subjects.
The age by sex interaction was nonsignificant for Cmax and
AUC? (p = 0.94 and p = 0.40, respectively).
The apixaban CLR tended to be lower in elderly subjects
(0.45 L/h) than in young subjects (0.63 L/h) and lower in
female subjects (0.46 L/h) than in male subjects (0.62 L/
h); these differences in CLR also appeared to be reflected in
CL/F (young versus elderly 6.1 versus 4.5 L/h; male versus
female 5.7 versus 4.9 L/h). The mean apixaban t in young
male subjects was approximately 10 h, whereas in young
female and elderly subjects it ranged from 14 to 16 h. A
weak increasing linear correlation was observed between
apixaban CL/F and CLcr (R2 = 0.2674, p\ 0.0001;
Fig. 2a) and between CLR and CLcr (R
2 = 0.1773,
p\ 0.0001; Fig. 2b). Among the relationships between
apixaban exposure (AUC? and Cmax) and other factors
(body weight and BMI) that were also explored, only
apixaban Cmax versus body weight showed a statistically
significant (p = 0.009) but weak (R2 = 0.09) negative
linear correlation.
3.3 Pharmacodynamics
Data from 39 subjects (6 young males, 12 young females,
11 elderly males and 10 elderly females) were included in
the summary and comparisons of apixaban pharmacody-
namics. Pharmacodynamic data from the first 40 subjects
enrolled in the study were excluded because of errors with
sample collection and processing techniques (such as
inadequate mixing of the sample, sustained application of
the tourniquet and repeated venepuncture in the same
location), which led to spuriously elevated clotting time
assessments regardless of age, sex or the plasma apixaban
concentration. Sample collection and processing tech-
niques have been shown to influence clotting time mea-
surements [20, 21]. Following retraining of the clinical site
on adequate mixing of blood with anticoagulant in the
sample tube and timely sample transfer, etc., clotting time
measurements showed greater consistency with prior
experience [7, 9].
The time course of the mean INR, mPT and anti-Xa
activity tracked the plasma concentration–time curve of
apixaban (Fig. 3), with maximum values for all pharma-
codynamic endpoints observed around the apixaban tmax
(3 h). Consistent with the pharmacokinetic profile in
elderly and young subjects, elderly subjects generally had
higher mean INR, mPT and anti-Xa values than young
subjects over the observed time course, but the differences
in the maximum mean (SD) INR, anti-Xa activity and mPT
between age groups were less than 15 %: INR, 1.55 (0.18)
and 1.46 (0.19); anti-Xa activity, 275 (75) and 295 (91) ng/
mL; mPT, 149 (25) and 130 (26) s in the elderly and young
groups, respectively. Similarly, the differences in the mean
(SD) AUC24 between age groups for these INR and mPT
assessments were less than 20 %: INR, 31.5 (2.23) and
29.3 (2.09); mPT, 2,604 (378) and 2,137 (295) sh in the
elderly and young groups, respectively.
The mean INR, mPT and anti-Xa activity profiles in
female subjects did not reflect the slightly higher apixaban
exposure observed in that group relative to male subjects,
with mean INR and mPT values being slightly lower in
females than in males, and no discernible difference in
anti-Xa. There were no substantial differences at maximal
values; the differences between sex groups were less than
15 % at maximum mean (SD) values: INR, 1.47 (0.12) and
1.56 (0.16); mPT, 132 (23) and 150 (33) s; anti-Xa activity,
292 (96) and 274 (60) ng/mL in female and male subjects,
respectively (Fig. 3). Furthermore, the differences in the
mean (SD) AUC24 between the sexes for these INR and
mPT assessments were less than 15 %: INR, 29.7 (1.58)





















Female (n = 39) 353.4 (31) 4,235 (28)a 4,116 (29) 3.0 (1.0, 4.0) 14.89 (7.06)a 0.46 (0.18) 4.91 (1.41) 79.7 (28.8)
Male (n = 40) 301.0 (26) 3,680 (30) 3,626 (30) 3.0 (1.0, 4.0) 12.60 (5.92) 0.62 (0.31) 5.69 (1.79) 82.8 (26.9)
Ratio of adjusted
GM, female to
male (90 % CI)
1.18 (1.06–1.31) 1.15 (1.04–1.27)
AUC? area under the plasma concentration–time curve from time zero extrapolated to infinite time, AUClast area under the plasma concentration–time
curve from time zero to the time of the last measurable concentration, CI confidence interval, CL/F apparent total clearance after oral administration,
CLR renal clearance, Cmax maximum observed plasma concentration, CV coefficient of variation, GM geometric mean, max maximum, min minimum,
SD standard deviation, t plasma terminal half-life, tmax time of Cmax, Vss/F apparent volume of distribution at steady state
a One young female subject was excluded from the summary statistics (and related analyses) for AUC? and t on the basis of predefined criteria
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and 31.5 (2.91); mPT, 2,248 (296) and 2,570 (476) sh in
female and male subjects, respectively. These findings
likely reflect limitations in the sensitivity of the respective
pharmacodynamic assays and their ability to accurately
detect small differences in apixaban exposure; however,
the anti-Xa activity appeared to better reflect the observed
apixaban concentration–time profiles of females and males.
There were no obvious differences in the plasma con-
centration–pharmacodynamic response relationships of
apixaban (Fig. 4a, b) across age or sex. The slope and
intercept (90 % CI) for the INR versus the apixaban con-
centration were 0.0021 (0.0017–0.0026) mL/ng and 1.09
(1.07–1.12), respectively; the slope and intercept (90 % CI)
for the mPT versus the apixaban concentration were 0.31
(0.28–0.33) mLs/ng and 61.7 (58.9–64.5) s, respectively.
A positive linear relationship was observed between indi-
vidual anti-Xa activity [expressed in apixaban units (ng/
mL)] and the corresponding plasma apixaban
concentrations (Fig. 4c). The slope and intercept (90 % CI)
for anti-Xa activity (expressed in ng/mL) versus the apix-
aban concentration were 0.85 (0.83–0.86) and 13.0
(8.7–17.2) ng/mL, respectively. When anti-Xa activity was
expressed in LMWH units of IU/mL, based on the kit
3-point standard curve (0–2 IU/mL), a similar linear rela-
tionship was observed over a narrower plasma apixaban
concentration range (approximately 0–200 ng/mL, as
shown in Fig. 4d). The slope and intercept (90 % CI) for
anti-Xa activity (expressed in IU/mL) versus the apixaban
concentration were 0.0134 (0.0130–0.0138) IU/ng and
0.048 (0.023–0.072) IU/mL, respectively. The relationship
between anti-Xa activity and the plasma apixaban con-
centration was less variable than that observed for the INR
and mPT (Fig. 4a–d).
3.4 Safety and Tolerability
A single 20 mg dose of apixaban was well tolerated by all
subjects in this study; there were no serious adverse events,
significant bleeding-related adverse events or discontinua-
tions due to adverse events. A total of 21 adverse events
were reported by 16 subjects; all were considered to be of
mild or moderate intensity. Seven subjects (including six
females) reported minor bleeding-related adverse events,
including three subjects with positive faecal occult blood
(one young female, one elderly female and one elderly
male), three subjects with ecchymosis (two young females
and one elderly female) and one subject (an elderly female)
with a haematoma secondary to venepuncture. All bleeding
events were mild in intensity and generally resolved within
1–7 days. The remaining adverse events consisted of
eczema, pruritus, headache, dizziness, iron deficiency
anaemia, blood draw site pain, cholelithiasis with elevated
transaminases, subcutaneous abscess, pharyngitis, cheilitis
and constipation, each occurring in one subject except for
headache (two subjects).
4 Discussion
Apixaban is approved for prevention of VTE following
elective knee or hip replacement surgery and for stroke
prevention in patients with NVAF; these patient popula-
tions tend to comprise elderly men and women [22–25].
Therefore, it is important to understand if age- or sex-
related differences influence the pharmacokinetics and
pharmacodynamics of agents used in the management of
these patients.
In this study, a single oral 20 mg dose of apixaban was
safe and well tolerated in all subjects, regardless of age or
sex. A 20 mg dose was chosen for this study because the
systemic exposure from a single 20 mg dose is
a
b
Regression equation: CLT/F = 2.231 + 0.031 x CLcr
R2 = 0.2674, p-value < 0.0001
Regression equation: CLR = 0.21075 + 0.00313 x CLcr
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Fig. 2 Linear regression of a apparent total clearance after oral
administration (CL/F) and b renal clearance (CLR) of apixaban versus
creatinine clearance (CLcr), by age groups. All subjects received
apixaban 20 mg. For CLR, one patient with a CLR of 2.08 L/h was
excluded from the statistical analysis
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representative of the steady-state exposure achieved with
the highest dose (10 mg twice daily) used in the apixaban
phase 3 clinical trials. Apixaban exposure was approxi-
mately 32 % higher in elderly subjects than in young
subjects and 15 % greater in female subjects than in male
subjects, indicating that age- and sex-related influences
have a small to modest impact on apixaban exposure. Age-
and sex-related influences on pharmacokinetics have been
attributed to multiple factors [10], several of which were
explored in this study, including associations between
apixaban exposure and renal function, body weight and
BMI. Among these factors, the strongest trend was
observed between apixaban exposure and renal function;
therefore, the relationship between apixaban CL/F and
renal function was explored further.
CLR accounts for approximately 27 % of total clear-
ance; therefore, a relationship between apixaban exposure
and renal function would be expected. In this study, CLR
and CL/F tended to be lower in elderly subjects than in
young subjects and lower in female subjects than in male
subjects. There was a direct relationship between apixaban
clearance and CLcr, which was consistent with the
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Fig. 4 Scatter plots of a the individual international normalized ratio
(INR), b the individual modified prothrombin time (mPT), c individual
anti-Xa activity levels (expressed in ng/mL of apixaban) and
d individual anti-Xa activity levels [expressed in IU/mL of low
molecular weight heparin (LMWH)] versus plasma apixaban
concentrations, by age (young: 18–40 years of age; elderly: C65
years of age) and sex groups. Data points that are above the upper
limit of the anti-Xa activity assay range (2 IU/mL, corresponding to
an apixaban concentration of *200 ng/mL) are not included in the
figure
Fig. 3 a, b International normalized ratio (INR), c, d modified
prothrombin time (mPT), e, f anti-Xa activity (expressed in ng/mL),
and g, h anti-Xa activity (expressed in IU/mL) versus time, by age
(young 18–40 years of age; elderly C65 years of age) and sex groups.
The error bars represent ±1 standard deviation
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and CLcr. These trends suggest that differences in renal
function may have contributed to the differences in apix-
aban CLR therefore reflected in the CL/F and exposure
observed between groups. While determining the effect of
renal function on apixaban pharmacokinetics was not an
aim of this study, the effect of renal impairment on apix-
aban pharmacokinetics has been evaluated in two other
studies—one in subjects with mild, moderate and severe
renal impairment, and another in subjects with end-stage
renal disease on haemodialysis [26, 27]. The results from
those two studies indicated that mild and moderate renal
impairment had a modest effect on the apixaban AUC; the
apixaban AUC was approximately 40 % greater in subjects
with severe renal impairment or end-stage renal disease
[26, 27]. Given that the range of CLcr in the current study
was 60–179 mL/min, consistent with the age range of the
subjects, the difference in CLR would partly contribute to
the observed differences in exposure between groups. The
apixaban t also appeared to be longer in elderly and
female subjects (elderly versus young 15.45 versus
11.98 h; female versus male 14.89 versus 12.60 h).
As noted, since only weak relationships were observed
between apixaban exposure and body weight and BMI, the
relationship between apixaban clearance and these two
demographic factors were not explored further in this
study. A study evaluating the impact of body weight on
apixaban pharmacokinetics has shown that apixaban
exposure is approximately 30 higher and 22 % lower in
individuals weighing\50 kg or[120 kg, respectively,
compared with subjects weighing 65–85 kg [27]. There-
fore, given the limited range of body weight in this study
(54–114 kg), it is not surprising that a weak association
between apixaban exposure and body weight and BMI was
observed.
As expected, changes in the pharmacodynamic measures
of INR, mPT and anti-Xa activity over time closely fol-
lowed the apixaban concentration–time profile. All three
measures exhibited a positive linear relationship with the
plasma apixaban concentration. Similar to what has been
previously reported, the relationship between the plasma
apixaban concentration and the INR and mPT is weaker
and more variable than the relationship between the plasma
apixaban concentration and anti-Xa activity [18]. This is
expected, since endogenous factors contributing to clotting
play roles in INR and mPT measurement, while the anti-Xa
activity assay used in this study relies on the addition of
exogenous bovine FXa, thus making the anti-Xa test more
dependent on an FXa inhibitor (apixaban) concentration
and less on other endogenous factors.
Measurement of anti-Xa activity using an apixaban
standard curve showed a positive linear correlation over the
full range of plasma apixaban concentrations (from 0 to
*700 ng/mL) observed in this study. Anti-Xa activity
determined using the kit LMWH standards also showed a
linear relationship, although over a narrower range of
apixaban concentrations (*0 to 200 ng/mL). It should be
noted that this was the first clinical study in which apixaban
anti-Xa activity was measured using the STA-Rota-
chrom heparin kit. Given the use of exogenous bovine
FXa in the Rotachrom assay and the pharmacological
characteristics of apixaban, the anti-Xa activity determined
with this assay is expected to correlate well with apixaban
concentrations. Therefore, any apparent discordance
between anti-Xa activity and apixaban concentrations
likely reflects assay limitations rather than a difference in
the pharmacological effect of apixaban. On the basis of the
results of this study, the STA-Rotachrom method was
further optimized for use in clinical trials and was used to
establish a direct linear correlation over a wider concen-
tration range between apixaban anti-Xa activity (expressed
in IU/mL) and the plasma apixaban concentration
(expressed in ng/mL) [18, 19]. Therefore, anti-Xa activity
may have utility as a bioassay for apixaban.
The small to modest effects of age and sex on apixaban
pharmacokinetics and pharmacodynamics observed in this
study are not likely to be clinically relevant, given the
favourable benefit–risk profile of apixaban observed in
phase 3 clinical trials. Elderly male and female patients
were included in the apixaban phase 3 clinical trials for
prevention of thromboembolism in knee and hip replace-
ment surgery (mean age *63 years; *40 % males) and
for stroke prevention in patients with AF (mean
age *69 years; 59–65 % males) [22–25, 29]. The 2.5 mg
twice-daily regimen was used in all phase 3 studies of
apixaban in VTE prevention, irrespective of patient age or
sex, and the efficacy and safety outcomes from those trials
confirmed that no dose adjustment is needed for age or sex
in that population [30]. The safety and efficacy profiles
observed for apixaban in the subpopulation analyses of the
phase 3 ARISTOTLE and AVERROES studies in patients
with NVAF also indicated that dose adjustment for age or
sex alone is not necessary [24, 25]. The ARISTOTLE and
AVERROES trials did have prespecified dose modification
criteria that included age as a component. Subjects with at
least two out of three risk factors for bleeding (age C80
years, body weight B60 kg and/or serum creati-
nine C1.5 mg/dL) received apixaban 2.5 mg twice daily
rather than 5 mg twice daily, which maintained the desired
safety and efficacy profiles in patients who met these cri-
teria [24, 25]. The individual impact of these factors on
apixaban exposure is modest and does not warrant dose
modification. Nevertheless, when they exist in combina-
tion, the resulting increase in exposure may warrant a
reduction in dose to mitigate the inherently higher risk of
bleeding that may be present in some patient populations
[26–29, 31].
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5 Conclusion
This study demonstrated that age- and sex-related influ-
ences on apixaban pharmacokinetics were small to modest
and do not appear to be clinically meaningful on the basis
of age and sex alone. Corresponding minor differences
were also present in pharmacodynamic markers of antico-
agulation activity. Anti-Xa activity showed a direct linear
relationship with plasma apixaban concentrations, regard-
less of age or sex groups, and appeared to be less variable
than other pharmacodynamic assessments, such as PT/INR.
Apixaban was well tolerated by all subjects in this study.
No dose adjustment is recommended for apixaban on the
basis of age or sex alone. However, in the presence of
multiple factors that increase apixaban exposure, dose
adjustment may be warranted, such as in AF patients with
at least two of these three risk factors for bleeding:
age C80 years, body weight B60 kg and/or serum creati-
nine C1.5 mg/dL.
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